Table 10.
Failed Anti-amyloid Drugs.
| Drug | Mechanism of Action | Results |
|---|---|---|
| Semagacestat | Anti-amyloid–γ-secretase inhibitor (23) | Lack of Efficacy |
| Avagacestat | Anti-amyloid–γ-secretase inhibitor (23) | Lack of Efficacy |
| Tarenflurbil | Anti-amyloid-γ-secretase modulation to make less toxic form of amyloid β (23) | Lack of Efficacy |
| Lanabecestat | Anti-amyloid–beta-secretase 1 cleaving enzyme (BACE) inhibitor (23) | Lack of Efficacy |
| Verubecestat | Anti-amyloid–beta-secretase 1 cleaving enzyme (BACE) inhibitor (23) | Lack of Efficacy |
| Atabecestat | Anti-amyloid–beta-secretase 1 cleaving enzyme (BACE) inhibitor (23) | Lack of Efficacy |
| Bapineuzumab | Anti-amyloid–binds N-terminal region of amyloid β at Residues 1–5 (25, 26) | Lack of Efficacy |
| Solanezumab | Anti-amyloid–bind amyloid β at Residues 16–26 (6, 25) | Lack of Efficacy |
| Gammagard Liquid | Anti-amyloid antibodies (23) | Lack of Efficacy |
| LMTM | Anti-tau aggregation (23) | Lack of Efficacy |
| ponezumab | Anti-amyloid–bind amyloid β at Residues 30–40 (6, 25) | Lack of Efficacy |
These are the past drugs that have failed clinical trials. This includes the mechanism of the drug and the reason for failure. This provides background into the drugs of amyloid beta.